Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03657095 · ClinicalTrials.gov registry record · Phase 3
A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension
A Phase 3 study, sponsored by Lung Biotechnology PBC.
- Terminated
- Registry status
- Phase 3
- Development phase
- 112
- Enrollment target
NCT03657095 is a Phase 3 study that was terminated before completion, run by Lung Biotechnology PBC. The registered enrollment target is 112 participants.
The verdict
NCT03657095, a Phase 3 study, was terminated before completion, sponsored by Lung Biotechnology PBC.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 112 participants
- Enrollment target
Study Summary
This is a multi-center, open-label study for eligible participants who were actively participating in the BPS-314d-MR-PAH-302 double-blind study (NCT01908699) at the time the study was concluded. This open-label extension (OLE) study will evaluate the safety, tolerability, and efficacy of long-term treatment with esuberaprost sodium tablets (Beraprost Sodium 314d Modified Release tablets).
Interventions
- DRUG Placebo
- DRUG Esuberaprost
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2018-12-10 |
| Est. Completion | 2019-07-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03657095
The ClinicalTrials.gov registry entry for NCT03657095 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lung Biotechnology PBC, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03657095 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03657095 about?
NCT03657095 is a clinical study titled "A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension". This is a multi-center, open-label study for eligible participants who were actively participating in the BPS-314d-MR-PAH-302 double-blind study (NCT01908699) at the time the study was concluded. This open-label extension (OLE) study will evaluate the safety, tolerability, and efficacy of long-term ...
What is the current status of trial NCT03657095?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 112 participants. The study started on 2018-12-10. Estimated completion is 2019-07-20.
What interventions are being tested in trial NCT03657095?
The interventions under investigation include: Placebo (DRUG), Esuberaprost (DRUG).
Who is sponsoring clinical trial NCT03657095?
This trial is sponsored by Lung Biotechnology PBC, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.